



Genocea Biosciences  
Investor Relations Department  
100 Acom Park Drive, 5th Floor  
Cambridge, MA 02140  
United States

Visit IR website [↗](#)  
Sign-up for Email alerts [↗](#)

#### NASDAQ: GNCA

|               |  |
|---------------|--|
| Last Trade:   | 5.90   |
| Trade Time:   | 4:00 PM ET<br>May 26, 2017                         |
| Change:       | -0.04 <span style="color: red;">↓</span> (-0.673%) |
| Day Range     | 5.83 - 6.02  |
| 52-Week Range | 3.28 - 7.29  |
| Volume        | 82,979   |

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

## Company Profile

Genocea aims to transform vaccine discovery and development to improve millions of lives. We use ATLAS™, our proprietary technology platform that rapidly identifies T cell antigens associated with protective immune responses in humans exposed to a pathogen. We have a pipeline of novel vaccine candidates that stimulate the T cell arm of the immune system, which is increasingly recognized as critical to generating protective immunity against a wide array of diseases. Genocea's pipeline includes clinical programs addressing genital herpes and pneumococcus and research efforts in... [\(more\)](#)

## Stock Performance



### Press Releases [\[ View all \]](#)

- May 4, 2017 [Genocea Reports First Quarter 2017 Financial Results and Positive Clinical Developments on Lead Candidate GEN-003 in Genital Herpes](#)
- Apr 27, 2017 [Genocea to Host First Quarter 2017 Financial Results Conference Call & Webcast on May 4, 2017 at 9 a.m. ET](#)
- Apr 11, 2017 [Genocea Awarded World Vaccine Congress 2017 Industry Excellence Award for Best Therapeutic Vaccine for GEN-003 for Genital Herpes](#)
- Mar 29, 2017 [Genocea to Present at the 16th Annual Needham Healthcare Conference](#)
- Mar 6, 2017 [Howard Mayer, M.D., of Shire, Joins Genocea Biosciences' Board of Directors](#)

### Financials [\[ View all \]](#)

- [First Quarter Financial Results](#)
- Feb 17, 2017 [Annual Report \(10-K\)](#)
- Apr 21, 2017 [Proxy Statement \(DEF 14A\)](#)
- May 5, 2017 [Quarterly Report \(10-Q\)](#)
- Nov 4, 2016 [Quarterly Report \(10-Q\)](#)
- Aug 5, 2016 [Quarterly Report \(10-Q\)](#)